Navigation Links
NPS Pharmaceuticals Announces Results of Tender Offer
Date:10/18/2007

al development. Additional information is available on the company's website, http://www.npsp.com.

This press release contains forward-looking statements intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to strategies, expectations, intentions, plans, future events, performance, underlying assumptions, and other statements that do not relate strictly to historical or current facts. Although NPS Pharmaceuticals' management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. These statements can be affected by inaccurate assumptions and by a variety of risks and uncertainties, including, among others, general economic conditions, the success of the tender offer for the 3.0% Convertible Notes due 2008 and the amount of any such notes actually tendered for repurchase or actually repurchased by the company, the company's reported results meeting the company's guidance and the expectations of the market, and other risks, including risks related to NPS Pharmaceuticals' operations and financial condition, detailed in NPS Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2006, NPS Pharmaceuticals' Quarterly Reports on Form 10-Q for the quarters ended March 31, 2007 and June 30, 2007 and any other reports of the company filed with the Securities and Exchange Commission. Should one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. NPS Pharmaceuticals does not undertake a
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today announced a litigation ... Incorporated v. Verizon Services Corp. et al. , Case ... the Eastern District of Virginia , ... 2015 interpreting certain key claims in favor of the ...
(Date:7/2/2015)... Memphis, TN (PRWEB) , ... July 02, 2015 ... ... in the development and manufacturing of surgical instruments in Orthopedics, announced today the ... orthopedic contract-manufacturing and the world's largest provider of surgical instruments to the Spine ...
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... Calif. , July 1, 2015   ... on the development of groundbreaking drugs to treat ... announced today that Robert G. Miller , ... at Sutter Health,s California Pacific Medical Center in San ... ALS Association for $1.5 million to help fund ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... , , , , ... stem cell based,technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical,team ... 36 year old Norwegian,patient in a hospital in Beijing. The ... stem cells as well as cancer daughter,cells. The amazing outcome ...
... ... Club, the Daveys, the GLOBALS, ,and PM360 Pharma Choice Awards Programs. , ... (PRWEB) December 17, 2009 -- ... advertising and marketing awards programs honoring exceptional creative and interactive work. , , ,THE ...
... test to find undetected landmines. Students from the University ... when it comes into contact with chemicals leaked by buried ... solution that, when sprayed on to the ground, forms green ... say that the organism, which is cheap to produce, could ...
Cached Biology Technology:For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4Goble & Associates Creative Work Awarded at Advertising Industry Competitions 2Goble & Associates Creative Work Awarded at Advertising Industry Competitions 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 4
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/16/2015)... Fingerprint Cards has received an order ... company,s portfolio from one of its module partners in ... place during the third quarter 2015. The sensors will be ... Jörgen Lantto, CEO of FPC, comments: " This ... interest from smartphone OEMs in integrating touch fingerprint sensors in ...
(Date:6/15/2015)... , June 16, 2015 ... Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies ... Forecast to 2020" published by MarketsandMarkets, The Natural Language ... at a CAGR of 18.4% for the forecast period ... and   46 F igures spread   through ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... that treatments targeting specific viral genes protected monkeys infected ... were protected even when therapeutics were administered one hour ... infections in laboratory or hospital settings. The research, ... Nature Medicine , was conducted by the U.S. ...
... Holt , a professor of plant physiology at the University ... film Avatar , will receive the Paul ... a distinguished scientist and educator" at a ceremony beginning at ... Garden, 230 Quail Gardens Drive, Encinitas, Calif. "This award ...
... New Compound May be Effective Against Chagas, Disease ... candidate against the deadly tropical infection, Chagas, disease say researchers ... 2010 issue of the journal Antimicrobial Agents and Chemotherapy ... parasite Trypanosoma cruzi and it affects approximately 18 ...
Cached Biology News:Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... 75 x 25 mm; ... recommended for immunohistochemistry of paraffin-embedded sections, ... end, markings will not ... precleaned, ...
Donor feline serum and plasma...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: